The role of cardiac MRI in the management of ventricular arrhythmias in ischaemic and non-ischaemic dilated cardiomyopathy by Nelson, T. et al.
This is a repository copy of The role of cardiac MRI in the management of ventricular 
arrhythmias in ischaemic and non-ischaemic dilated cardiomyopathy.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/150427/
Version: Published Version
Article:
Nelson, T., Garg, P. orcid.org/0000-0002-5483-169X, Clayton, R.H. 
orcid.org/0000-0002-8438-7518 et al. (1 more author) (2019) The role of cardiac MRI in 
the management of ventricular arrhythmias in ischaemic and non-ischaemic dilated 
cardiomyopathy. Arrhythmia & Electrophysiology Review, 8 (3). pp. 191-201. ISSN 
2050-3369 
10.15420/aer.2019.5.1
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) 
licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new 
works must also acknowledge the authors and be non-commercial. You don’t have to license any derivative 
works on the same terms. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
191©  R A D C L I F F E  C A R D I O L O G Y  2 0 1 9 Access at: www.AERjournal.com
Electrophysiology and Ablation
Ventricular tachycardia (VT) and VF occur mainly in people with 
impaired cardiac function and/or ischaemic heart disease, and account 
for the majority of sudden cardiac deaths worldwide.1 Treatment with 
anti-arrhythmic drugs such as amiodarone may be at best neutral in 
terms of mortality and carries significant long-term risks.2,3 While ICDs 
significantly improve survival for patients with significantly impaired 
left ventricular ejection fraction (LVEF), the devices also carry risks of 
infection and inappropriate shocks being given.4,5 
Some patients may present with a ‘secondary prevention’ ICD 
indication such as sustained VT or VF arrest, but, in the primary 
prevention setting, the risk of arrhythmia is based on the presence 
and severity of structural heart disease. Selection of patients in this 
way lacks precision and fails to identify some at-risk patients while 
leading to overtreatment in others. Current guidelines recommend 
echocardiography as the first-line investigation for cardiac function due 
to ease of access, because the echocardiographic equipment is usually 
available in heart clinics, whereas cardiac MRI (CMRI) services currently 
tend to only be available in specialist (tertiary) centres.6 However, 
CMRI is superior in terms of both accuracy and reproducibility when 
quantifying LVEF and myocardial mass, and can overcome limitations 
of inadequate echocardiographic windows. CMRI offers a one-stop 
investigation for accurately establishing cardiac structure, function and 
myocardial tissue characterisation. 
Understanding the Substrate for Ventricular 
Arrhythmia
Ischaemic Cardiomyopathy
Studies of cardiac tissue obtained before transplantation or following 
left ventricular (LV) aneurysm surgery, as well as more recent human 
and animal CMRI studies, have confirmed our understanding of the 
structural changes that occur in ischaemic cardiomyopathy (ICM). 
Strands of surviving tissue within and at the periphery of the infarct 
region form tortuous and slowly-conducting channels which support 
re-entry, so the infarct border zone frequently has a heterogeneous 
appearance on CMRI.8–10 
Fenoglio et al. demonstrated there were bundles of surviving myocytes 
in endocardial resection samples; some of these had a diameter 
of <100  µm, but it was not known which of these channels were 
mechanistically important.11 De Bakker et al. showed that differential 
slow conduction occurs with multiple tracts <200 µm.9 Recently, ultra-
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high (submillimetre) resolution ex vivo CMRI of infarcted porcine hearts 
showed conducting pathways were mainly subendocardial.12 However, in 
this study, a significant minority of pathways were observed to be entirely 
epicardial and would be inaccessible for endocardial catheter ablation. 
Urgent reperfusion (by either thrombolysis or angioplasty) for MI 
reduces infarct size and the incidence of subsequent chronic VT. In 
observational studies, VT cycle lengths were shorter, possibly suggesting 
a smaller circuit, in patients who had received revascularisation than 
in those who had not been revascularised.13–15 This would suggest that 
reperfusion strategies can introduce greater substrate heterogeneity 
within the infarcted area. 
Techniques that characterise and quantify the scar border zone or 
identify channels could improve risk stratification and treatment 
planning. However, while larger conducting channels may be identified 
using CMRI, it is likely that others are missed because of the limited 
spatial resolution of current clinical imaging. Where channels are too 
small to be visualised, measures of tissue heterogeneity may act as 
surrogates for the presence of ‘sub-resolution’ channels. 
Non-ischaemic Cardiomyopathy
The aetiology of VT in patients with non-ischaemic cardiomyopathy 
(NICM) is less well understood, partly because of the heterogeneity 
of underlying pathological processes in NICM. When regional fibrosis 
is detectable, it is often midwall or subepicardial, making access 
for catheter ablation challenging. These factors may explain why 
outcomes from NICM VT ablation are worse than those in ischaemic 
cardiomyopathy.16
In contrast to macro re-entrant VT, polymorphic VT or VF may occur 
due to distinct (but related) mechanisms. Replacement fibrosis can 
be patchy and/or diffuse, with disruption of the left ventricular 
microarchitecture.17 This diffuse fibrosis provides the substrate for 
conduction block and micro re-entry resulting in VF.18,19 This substrate 
is often dynamic with progressive fibrosis, reducing the long-term 
efficacy of targeted substrate modification.
Cardiac MRI Tissue Characterisation
Late Gadolinium Enhancement
Late gadolinium enhanced (LGE) CMRI imaging has become the de 
facto standard for imaging myocardial fibrosis. This approach uses 
gadolinium as a contrast agent to highlight areas of heterogeneity within 
the myocardium (e.g. fibrotic versus normal areas). In normal tissue, 
the washout of gadolinium is rapid, whereas in areas of myocardial 
fibrosis the washout is slower. By timing the image acquisition to occur 
‘late’ when washout has occurred in normal tissue but not in fibrotic 
tissue, regions of normal and fibrosed tissue can be differentiated. This 
technique relies on setting the inversion time to ‘null’ distant normal 
myocardium, making it appear black. Areas of enhancement have been 
demonstrated to correlate well with both acute myocardial necrosis 
and chronic fibrosis in ischaemic pathological specimens as well as 
replacement fibrosis in non-ischaemic dilated cardiomyopathy.20,21 
Typical image resolution is 1.4 × 1.4 × 10 mm (the 10 mm distance is 
the gap between slices). 
Quantification of Late Gadolinium Enhancement 
Although a narrative report of scar distribution is typically given in 
clinical use, the volume of abnormal tissue can also be quantified based 
on signal intensity (SI). Manual planimetry requires the operator to 
manually identify areas of fibrosis, whereas semi-automated standard 
deviation (SD) or full width at half maximum (FWHM) techniques require 
less user input. The SD method defines abnormal voxels with more than 
2, 3, 4, 5 or 6 standard deviations greater than the SI in a user-defined 
region of ‘normal’ myocardium. The FWHM method identifies tissues 
that fall below the SI of a user-defined area of fibrosis. Typical FWHM 
thresholds define a dense scar as one with >50% peak SI and a border 
zone between 35% and 50%.22–24 These techniques generate either a 
mass or percentage value of affected myocardium for the total scar 
burden, or for subdivisions of border zone and scar core. Although these 
techniques are reproducible, depending on the method and threshold 
chosen, significant inter-method variation is seen, and there is limited 
comparison with the gold standard of pathological specimens.25 In a 
small series, FWHM method correlates best with pathological specimens 
in animals and with manual segmentation in humans with ICM.24,26 
T1 Mapping
Conditions with diffuse tissue fibrosis are more challenging to detect 
with LGE if there are no unaffected myocardial segments. Measurement 
of absolute T1 relaxation values sidesteps the requirement for tissue 
inhomogeneity in LGE imaging. Spatial resolution is inferior to LGE 
imaging at approximately 1.4 × 1.9 × 6 mm and is challenging at higher 
heart rates, though native T1 mapping does not require the use of a 
contrast agent.27 As imaging protocols, field strength and acquisition 
methods vary, reference T1 values are specific to the vendor/
manufacturer. 
Unlike LGE, native T1 values are frequently abnormal in diffuse diseases 
of the myocardium, giving insights into the aetiology of NICM. T1 values 
are increased by tissue oedema and fibrosis, and are reduced by 
lipid overload (e.g. in Anderson-Fabry disease) and iron overload.28 
For clinical use, mid-myocardial septal values for T1 are reported, 
though a map can be generated showing the native T1 values across 
an imaging slice. The T1 map may highlight focal areas of oedema as 
seen in acute myocarditis, acute myocardial infarction or takotsubo 
cardiomyopathy.29,30
Extracellular Volume 
Contrast-enhanced T1 mapping allows the extracellular volume (ECV) 
to be estimated. By comparing pre- and post-contrast T1 values 
(referencing the T1 values of the blood pool and the patient’s 
haematocrit), a value for ECV is obtained. This is expressed as a 
fraction of the tissue volume; published normal values for ECV are 
approximately 25%.31,32 While native T1 values examine entire tissues, 
ECV characterises only the extracellular matrix and is therefore less 
affected by acute oedema. Higher ECV values are seen with expansion 
of the interstitium due to fibrosis or deposition and therefore correlate 
well with fibrotic changes at endomyocardial biopsy.33,34
As with native T1, ECV can be expressed as a global value or as a map 
highlighting regional variation. While ECV is raised in areas of chronic 
infarction, its main advantage over LGE for arrhythmic risk stratification 
is its potential to identify diffuse myocardial fibrosis in NICM.28,35 
T2 Imaging
Acute myocardial injury results in interstitial oedema. This occurs 
rapidly after myocardial infarction, and T2-weighted CMRI sequences, 
which identify oedema, can predict final infarct size.36 In chronic 
conditions such as cardiac sarcoidosis, myocarditis, transplant 
rejection and toxic cardiomyopathies, T2-weighted imaging accurately 
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identifies myocardial oedema.37 While arrhythmic complications in 
these conditions may be predicted using CMRI, there is limited data 
to support T2 imaging for arrhythmic risk stratification in patients with 
ICM or NICM.38 
Comparison of Techniques
LGE CMRI identifies the aetiology of left ventricular systolic dysfunction 
(LVSD), and permits the identification and quantification of myocardial 
fibrosis. As a semi-quantitative technique, LGE can demonstrate only 
relative differences between fibrotic and non-fibrotic myocardium. As 
a result, diffuse diseases of the myocardium may be missed with this 
technique. Newer techniques such as T1 and ECV mapping have the 
advantage of being quantitative and, as such, can be used to identify 
such diffuse myocardial fibrosis seen in some forms of NICM. Table 
1 demonstrates these differences. Examples of these techniques are 
shown in Figure 1 and Figure 2.
 
Current Clinical Application of Cardiac MRI
Current guidelines recommend echocardiography as the firstline 
investigation in patients presenting with heart failure or VT, although CMRI 
gains a class I recommendation if an infiltrative cause is suspected.39,40 
With echocardiography or CMRI, regional wall motion abnormalities and 
wall thinning suggest an ischaemic aetiology, while global hypokinesis 
supports a non-ischaemic cause. However, assessment is highly 
dependent on image quality and CMRI can overcome inadequate 
echocardiographic windows.39 In patients presenting with VT, CMRI is 
particularly useful for identifying inflammatory or infiltrative aetiology as 
well as ischaemic and non-ischaemic cardiomyopathies. In one series, 
CMRI changed the working diagnosis in 50% of patients presenting with 
VT/VF.41 Myocardial infarction shows a subendocardial to full thickness 
pattern of LGE, which will conform to one or more coronary territories. 
Conversely, non-ischaemic dilated cardiomyopathy often has a more 
diffuse pattern of fibrosis.17 As a result, the location of regions highlighted 
by LGE in such patients is variable, but it is more commonly located in the 
midwall or epicardial regions of anteroseptal or inferolateral segments.42 
 
Revascularisation of hypokinetic non-infarcted chronically ischaemic 
tissues may result in functional recovery.43 Hyperenhancement 
transmurality in LGE CMRI correlates well with myocardial recovery 
after revascularisation. In a series of 50 patients, regions with ≤25% 
transmurality were likely to demonstrate improved contractility, while 
those with >50% transmurality showed poor functional recovery 
after revascularisation.20 
 
When myocardial ischaemia causes polymorphic VT/VF, revascularisation 
is indicated. However, in patients with sustained monomorphic VT, 
revascularisation is more contentious, since monomorphic VT usually 
reflects established substrate that may not be altered by revascularisation. 
Indeed, in a case series of 65 patients with coronary disease and VT/
VF, surgical revascularisation did not appear to affect inducibility of 
Table 1: Comparison of Myocardial Tissue Characterisation Techniques
Measurement Scar identification/ 
quantification
Scar density 
estimation
Quantification 
of scar border 
zone
Identification 
of diffuse 
fibrosis
Evidence for use as a 
decision aid for risk 
stratification
Late gadolinium enhancement Semi-quantitative +++ − ++ − ++ (ICM)
+++ (NICM)
T1 mapping Quantitative + + − + +
Extracellular volume mapping Quantitative ++ +++ + +++ +/−
ICM = ischaemic cardiomyopathy; NICM = non-ischaemic cardiomyopathy.
Figure 1: Ischaemic Cardiomyopathy: Image Comparison
LGE
T1 map
200 ms 1,600 ms
ECV map
0% 100%
Anterior MI
Ischaemic cardiomyopathy secondary to an anterior ST-elevation MI. In this short axis slice, 
there is subendocardial LGE in the left ventricular anterior wall. T1 native values are elevated 
in the same region. ECV demonstrates this is a dense scar (ECV >55%). ECV = extracellular 
volume; LGE = late gadolinium enhancement.
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arrhythmia, but was associated with good long-term outcomes.44 Several 
other observational studies have similarly found that a reduction in 
mortality is associated with either PCI or surgical revascularisation in 
patients presenting with VT/VF.45–49 
Cardiac MRI Risk Stratification
Current European Society of Cardiology guidelines for ICD implantation 
(in both ICM and NICM) are based upon LVEF and New York Heart 
Association class but not formal scar quantification.6 The more recent 
2017 American Heart Association guidelines differ slightly, with a 
class IIa recommendation given for the use of CMRI imaging to aid risk 
stratification in patients with suspected NICM.40 
To investigate the role of CMRI as a tool for risk stratification, 
PubMed was searched using the terms (‘Risk Assessment’[Mesh] 
OR ‘Prognosis’[Mesh] OR ‘Predictive Value of Tests’[Mesh]) AND 
(‘Myocardial Ischemia’[Mesh] OR ‘Dilated Cardiomyopathy’[Mesh]) 
AND (‘Magnetic Resonance Imaging’[Mesh]) OR ‘Gadolinium’[Mesh]) to 
identify studies using CMRI to guide risk stratification. These studies 
are summarised in Table 2. 
Ischaemic Cardiomyopathy
The presence of LGE with CMRI imaging strongly predicts mortality 
in patients with ischaemic cardiomyopathy, independently of LVEF, 
including in patients without detectable LVSD.50–52 Total scar burden 
correlates with mortality and ICD discharges, even in multivariate 
models including LVSD (Table 2).51–56 Quantification of the scar border 
zone (rather than scar core) or quantifying the number of peri-infarct 
channels are alternative approaches to predicting VT/VF events.57–60 
Non-ischaemic Cardiomyopathy
As in ICM, the presence of LGE on CMRI in patients with NICM strongly 
predicts mortality and arrhythmic events across the spectrum of LV 
impairment.21,61–63 Patients with fibrosis identified by LGE are also 
less likely to achieve reverse remodelling with medical therapy.64 
The spatial distribution of fibrosis is also important, with septal 
scarring conferring a higher risk of sudden cardiac death (SCD) than 
inferolateral variants, and subepicardial scarring conferring a higher 
risk than linear mid-wall fibrosis.65 
 
Although patients with a low LVEF (<35%) have the highest individualised 
risk of SCD, this accounts for only ~20% of all cardiac arrests. The great 
majority of cardiac arrests occur outside this high-risk category.1 
Patients with fibrosis identified by LGE have worse outcomes than 
those without and risk stratification of individuals based on the 
presence or absence of LGE rather than on LVEF alone may aid patient 
selection for ICDs.66 For example, compared with all those with LVEF 
<35% (i.e. using echocardiographic risk stratification alone), those with 
an LVEF >35% and LGE have similar risks of SCD.63 Moreover, these 
selected patients with preservation of pump function will often have a 
lower competing risk of non-arrhythmic death. 
In contrast with ICM, where scar-related monomorphic VT predominates, 
patients with NICM are more likely to experience polymorphic VT and 
VF.67 On a review of the literature, most studies examining CMRI for risk 
stratification in NICM do not differentiate between VT and VF (Table 
2). This practical approach is helpful for treatment decisions. However, 
Piers et al. found that scarring predicts monomorphic VT but not 
polymorphic VT or VF, suggesting that factors other than macroscopic 
anatomical substrate may be important in arrhythmogenesis in NICM.68
Patients with NICM with no evidence of fibrosis on CMRI have fewer 
arrhythmic events, a lower risk of death and a higher likelihood of 
reverse remodelling. Careful patient selection for prophylactic ICD 
implantation in this population is required, and it therefore seems 
logical that identification of fibrosis using CMRI could more accurately 
identify those who would benefit, particularly patients with NICM and 
those with an LVEF >35%. However, no trial data exist to supports 
this approach. 
Late Enhancement 
There is now persuasive evidence that quantification of the scar and/
or border zone burden can be used to help risk stratify patients with 
both ICM and NICM, in addition to measures of LVEF. The fact that this 
relationship exists across the range of LVSD suggests that fibrosis 
itself is an important determinant of arrhythmic risk, rather than being 
simply a marker of end-stage disease. 
While the presence of any degree of LGE predicts risk in both NICM 
and ICM, quantification of scar extent only appears to add substantial 
incremental risk prediction benefit in patients with ICM. However, 
the clinical applicability of fibrosis quantification is limited by a lack 
of consensus over which scar metrics and thresholds are the best 
predictors of outcomes, or how to apply these metrics to individuals.69
Figure 2: Non-ischaemic Cardiomyopathy: 
Image Comparison
These two cases of non-ischaemic cardiomyopathy highlighting the utility of LGE, T1 and ECV. 
LGE+ is a case with mid-myocardial fibrosis (orange arrows), with globally high ECV. LGE− did 
not demonstrate any fibrosis on LGE imaging but had high native T1 and globally raised ECV, 
confirming the diagnosis of non-ischaemic cardiomyopathy. ECV = extracellular volume; 
LGE = late gadolinium enhancement.
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Table 2: Prognostic Impact of Cardiac MRI
Author n Method for Scar  
Quantification
HR for Adverse Outcome (95% CI) Result
Ischaemic Cardiomyopathy
Bello et al. 200554 48 ≥2 SD above remote normal 
myocardium
Not given, p=0.02 Greater infarct mass and infarct surface area 
predicts inducible VT at EPS
Yan et al. 200658 144 ≥2 SD above remote normal 
myocardium
1.45 (1.15–1.84) per 10% increase in scar 
border zone
Extent of the peri-infarct zone defined 
by delayed-enhancement CMRI is an 
independent predictor of post-myocardial 
infarction all-cause and cardiovascular 
mortality, after adjusting for LV volumes 
or LVEF
Schmidt et al. 2007119 47 FWHM Not given, p=0.02 Border zone mass was higher in those with 
inducible VT than those with no inducibility, 
but there was no difference in scar core 
mass
Roes et al. 2009120 91 FWHM (35-50%) 1.49 1.01–2.20) per 10 g increase in scar 
border zone.
Extent of infarct border zone is the strongest 
predictor of subsequent ICD therapy
Kwon et al. 200950 349 ≥2 SDs above remote normal 
myocardium
1.02 (1.003–1.03) per 1% increase in  
LV scar
Scar mass predicts mortality or 
transplantation
Kelle et al. 2009121 177 Number of AHA 17 segment 
model with enhancement
1.27 (1.064–1.518) per additional 
enhanced segment
Number of AHA segments involved predicts 
death and non-fatal myocardial infarction. 
Heidary et al. 201057 70 FWHM border zone (remote max 
to 50%), FWHM scar core (>50%)
Not given, p=0.03 Total scar mass and border zone mass 
(but not scar core mass) predict adverse 
outcomes
Scott et al. 201153 64 The number of transmural scar 
segments (using AHA 17 segment 
model)
1.48 (1.18–1.84) in multivariate analysis The number of transmural scar segments 
predicts subsequent ICD therapies
Krittayaphong et al. 2011122 1,148 Visual presence of LGE 3.92 (1.98–7.76) in multivariate analysis LGE predicts MACE in a cohort with normal 
wall motion.
Boyé et al. 2011123 52 ≥5 SD Not given, p=0.02 Infarct mass expressed as a percentage of LV 
mass predicts appropriate device therapy
Rubenstein et al. 201359 47 Between 2 and 3 SD above 
remote normal myocardium
1.97 (1.04–3.73) per 1% change in border 
zone mass in multivariate analysis
Border zone mass higher in those with VT 
inducibility (2.64% of LV mass) than those 
without (1.35%)
Alexandre et al. 2013124 49 Scar mass by manual planimetry 1.08 (1.04–1.12) unadjusted, 3.15 
(1.35-7.33) in multivariate analysis 
(per 1g extra scar mass)
Scar mass predicts appropriate device 
therapy
Kwon et al. 2014125 450 ≥2 SD above remote normal 
myocardium
1.34 (1.15–1.55) in multivariate analysis Scar percentage strongly predicts mortality
Demirel et al. 2014126 99 FWHM 2.01 (1.17–3.44) in multivariate analysis Ratio of peri-infarct border zone to scar core 
is associated with appropriate ICD therapy
Rijnierse et al. 2016127 52 FWHM (>50%) Not given, p=0.07 Trend towards higher scar burden in those 
with inducible VT (not significant)
Non-ischaemic Cardiomyopathy
Assomull et al. 200662 101 Visual presence of midwall LGE 3.4 (1.4–8.7) for presence of LGE Presence of midwall fibrosis predicts death 
or hospitalisation
Wu et al. 200861 65 Visual presence of LGE 8.2 (2.2–30.9) in multivariate analysis Presence of LGE predicts cardiovascular 
death, ICD therapy and HF hospitalisation
Iles et al. 2011128 61 Visual presence of LGE Not given, p=0.01 Patients with LGE had significantly higher 
rates of appropriate ICD therapy
Lehrke et al. 2011129 184 Visual presence of LGE, SD >2 
for quantification
3.5 for presence of scar. 5.28 using 
threshold of scar >4.4% total LV mass
Presence of LGE predicts cardiac death, ICD 
therapy or HF hospitalisation
Neilan et al. 2013130 162 Both FWHM and SD methods  
used
14.5 (6.1–32.6) for LGE presence, 1.15 
(1.12–1.18) for each 1% increase in scar 
volume
Presence and volume of LGE predicts 
cardiovascular death or ICD therapy
Gulati et al. 2013131 472 Visual presence, FWHM 2.96 (1.87–4.69) for presence of LGE, 
1.1 (1.06–1.17) per 1% extra LGE
LGE presence, extent predicts mortality, 
independently of LVEF
Machii et al. 2014132 72 Visual presence of LGE Not given, p=0.02 for extensive LGE 
versus no LGE
Lower event-free survival in patients with 
extensive LGE
(Continued)
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Extracellular Volume and T1 Mapping for Risk 
Stratification
Alternative metrics, such as native T1 values and ECV, measure diffuse 
myocardial fibrosis. In patients with both ICM and NICM, myocardial 
T1 values (at sites spatially discrete from areas of LGE) incrementally 
improved risk stratification in a model that already included LVEF, QRS 
duration, and metrics of scar core and border zone (using LGE).70 In 
a similar study using ECV rather than T1, high ECV values correlated 
with mortality.71 In two small case series, high ECV values correlated 
with ICD therapies.35,72 These studies suggest that, when dense scar is 
surrounded by diffusely fibrotic myocardium, VT/VF is more likely than 
if the scar is encompassed by normal myocardium. 
 
ECV and T1 mapping techniques have a sound physiological basis for 
identifying diffusely abnormal myocardium not identified with LGE 
imaging. ECV is of particular interest as a marker of risk in patients 
with NICM who do not have identifiable LGE, since it offers the ability 
to identify diffuse interstitial fibrosis. Complementary assessment of 
diffuse and regional disease by ECV mapping and LGE respectively 
may provide incremental benefit for risk stratification in both ICM and 
NICM. ECV may also have value in further characterising the density of 
discrete scars, although data to support this use are limited. 
Ablation for Ventricular Tachycardia
For patients with a high burden of VT, catheter ablation can successfully 
reduce ICD shocks.73–75 These procedures can be challenging, with 
significant morbidity and mortality, since VT is frequently poorly 
tolerated and precise localisation of re-entrant circuits using traditional 
electrophysiological techniques is often challenging. VT ablation 
therefore often targets the myocardial scar substrate.76 Differing 
approaches to substrate ablation have been described – linear 
transection, core isolation, scar homogenisation or abolition of late 
Table 2: Cont.
Perazzolo-Marra  
et al. 2014133
137 Visual presence of LGE 3.8 (1.3–10.4) in multivariate analysis LGE presence, but not extent, predicts 
adverse arrhythmic outcome
Masci et al. 2014134 228 Visual presence of LGE 4.02 (2.08–7.76) in multivariate analysis LGE presence predicts adverse outcomes 
in patients with asymptomatic LVSD
Piers et al. 201568 87 Visual presence, FWHM 2.71 (1.10–6.69) for LGE presence LGE predicts monomorphic VT, but not 
polymorphic VT/VF
Shin et al. 2016135 365 FWHM 8.45 (2.91–24.6) for LGE extent ≥ 8%, 
increasing to 6.98 (1.74–28.0) for those 
with subepicardial pattern of disease
Presence of LGE strongly predicts arrhythmic 
events, risk varies with location of fibrosis
Mueller et al. 2016136 56 Visual presence of LGE 1.9 (1.1–3.4) Presence of LGE predicts VT inducibility
Puntmann et al. 2016137 637 T1 mapping 1.1 (1.07–1.17) per 10 ms change in T1 
time, multivariate analysis
Higher T1 values predict mortality and HF 
outcomes
Halliday et al. 201763 399 Visual presence of LGE, FWHM 
for quantification
9.2 (3.9–21.8) in patients with LVEF > 40% A 17.8% event rate (median follow-up  
4.6 years) in patients with LGE
Halliday et al. 201665 874 FWHM LGE extent of 0 to 2.55%, 2.55% to 
5.10%, and >5.10%, respectively, were 
1.59 (0.99 to 2.55), 1.56 (0.96 to 2.54), 
and 2.31 (1.50 to 3.55) for all-cause 
mortality 
The presence and pattern, rather than the 
extent, of LGE predicts all-cause mortality
Studies Including Both ICM and NICM
Kwong et al. 2006138 195 ≥2 SD 8.29 (3.92–17.5) unadjusted, 8.65 
(2.45–30.5) in multivariate analysis
Presence of LGE predicts cardiac events in 
patients with suspected CAD
Klem et al. 201151 1560 Number of segments with LGE 1.007 (1.005–1.009) unadjusted, 1.004 
(1.002–1.007) in multivariate analysis
Number of segments with LGE incrementally 
prediction of all-cause mortality over LVSF 
and clinic parameters
Gao et al. 201256 124 ≥2 SD 1.4 (1.21–1.62) unadjusted Scar quantification predicts arrhythmic 
events
Dawson et al. 2013139 373 Visual presence of LGE, FWHM 
for quantification
3.5 (2.01–6.13) for presence of LGE,  
1.12 per 5% extra LGE
In patients presenting with VT, LGE predicts 
arrhythmic events
Almehmadi et al. 2014140 318 ≥5 SD 2.4 (1.2–4.6) in multivariate analysis Midwall striation predicts sudden death or 
appropriate ICD therapy
Chen et al. 201570 130 Native T1 value 1.1 (1.04–1.16) per 10 ms change in T1  
time, multivariate analysis
Myocardial T1 predicts ventricular arrhythmia 
independently of scar quantification
Mordi et al. 2015141 539 Visual presence of LGE 2.14 (1.06–4.33) in multivariate analysis LGE predicts MACE in all-comers attending 
for CMRI
Acosta et al. 201860 217 FWHM 40–60% (border zone), 
>60% (scar core)
1.06 (1.04–1.08) for border zone mass (g) Scar mass, border zone mass and border 
zone channel mass all predict ICD therapy 
or SCD
Olausson et al. 201835 215 ECV 2.17 (1.17–4.00) for each 5% increase 
in ECV
Diffuse fibrosis (as evidenced by ECV) 
predicts appropriate ICD therapy
Studies showing the prognostic effect of CMRI data in ischaemic cardiomyopathy and non-ischaemic cardiomyopathy. AHA = American Heart Association; CMRI = cardiac MRI; 
EPS = electrophysiology study; ECV = extracellular volume; FWHN = full width at half maximum; HF = heart failure; LGE = late gadolinium enhancement; LV = left ventricle; LVEF = left 
ventricular ejection fraction; MACE = major adverse cardiac event; VT = ventricular tachycardia.
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potentials.77–80 Often, this requires extensive, time-consuming ablation 
in haemodynamically fragile individuals, which could be streamlined 
with a more detailed appreciation of the underlying substrate. CMRI 
can be used to predict the location of re-entrant circuits and channels 
within the scar to guide ablation lesions, the success of which can be 
predicted by computer modelling.81,82
Planning
The configuration of LGE on CMRI allows the operator to estimate 
the likelihood of successful ablation and identify whether epicardial 
access is required. Predominantly subendocardial ischaemic scar-
related VT is usually treatable with endocardial ablation.75 Conversely, 
VT ablation in NICM may be hampered by inaccessibility of the 
substrate, and epicardial access may be required for patients with 
inferolateral and/or subepicardial scarring.83 Epicardial access is 
typically not required for patients with VT originating from a septal 
intramural scar, although outcomes from ablation of ‘deep’ substrate 
are poorer, as might be expected.84 
Image Fusion 
Conventional 3D electroanatomical maps (EAMs) generated during 
ablation procedures may be inaccurate because of poor catheter 
contact or reach, and contact mapping of entire cardiac chambers is 
time consuming. 
Clinical CMRI studies can be reconstructed into 3D geometries 
demonstrating the distribution of a scar (Figure 3). With further refinement 
using 3D acquisition and image-processing methods, channels that 
might facilitate re-entry can be identified in advance (Figure 4).85 These 
geometries can be used simply as a road map for the operator during 
ablation procedures. Alternatively, fusion of these 3D geometries with the 
EAM system can leverage the accurate and high resolution anatomical 
detail of clinical imaging, allowing the operator to observe CMRI (and/or 
CT) images directly in the mapping software to reduce the time spent 
generating EAMs.86–89 Contact mapping can be focused on regions of 
interest determined in advance, e.g. by using algorithms for localising the 
VT origin based on 12-lead ECG morphology or by non-invasive mapping 
(ECGI) techniques.90–95 While image fusion has the potential to streamline 
ablation procedures, as yet, the benefits of such an approach have not 
been formally evaluated, and widespread applicability is not assured 
since it requires significant clinical and imaging expertise. 
Future Directions
Overcoming Technical Limitations of Cardiac MRI
Many patients at risk of VT/VF have cardiac implantable electronic 
devices (CIEDs).96 Historically, MRI has been contraindicated in patients 
with CIEDs due to safety concerns. However, with advances in CIED 
technology such as MRI-conditional devices, growing experience 
and appropriate precautions and monitoring, CMRI can often be 
performed safely even in patients with historic non-conditional 
devices.69,97,98 Nevertheless, images may be significantly degraded by 
the presence of CIEDs, particularly the anteroseptal regions of the left 
ventricle in patients with left-sided pulse generators that lie in close 
proximity to the heart. Wideband sequences are described which can 
reduce these artefacts.99 
LGE imaging is usually obtained by multiple short axis planes through the 
heart. This results in excellent in-plane resolution, but a large slice width 
(approximately 10 mm) between images. Reconstructions of the heart can 
suffer with a ‘partial voluming’ artefact that can overestimate the infarct 
border zone.100 This effect can be mitigated by evolving techniques such 
as 3D image acquisition or super-resolution image reconstruction.101,102
Histological studies have demonstrated myocyte fibre disarray at the 
border zone of a chronic infarction.103 Due to anisotropic conduction 
of myocytes, knowledge of fibre orientation is potentially important 
to understand propensity to arrhythmia. Diffusion tensor imaging 
can demonstrate fibre direction and may therefore inform computer 
models of arrhythmia, although this use of CMRI is in its infancy.12,104,105
Ventricular Tachycardia Stimulation and Modelling
Inducibility of VT during an electrophysiology study (EPS) by programmed 
ventricular stimulation (PVS) pacing from a right ventricular site predicts 
arrhythmic events in ICM.106 This meta-analysis demonstrated PVS had 
the power to predict subsequent arrhythmic events (pooled OR 4.00, 
95% CI [2.30–6.96]). Depending on patient selection and the number 
of extrastimuli used, the sensitivity, specificity and predictive value of 
this test varies, although is not commonly used clinically due to its 
invasiveness, cost and insufficient negative predictive value. In NICM, 
assessment with PVS is less well studied and probably less effective 
than with ICM.107 
Figure 3: Image Post-processing of 2D Cardiac MRI Images
A B C
Short axis late gadolinium enhancement images (A) are contoured to identify endo- and 
epicardial boundaries, before a full width at half maximum thresholding approach identifies areas 
of dense scar (red) and border zone (yellow), then (B) the short axis stack is reconstructed to 
form a 3D volume (C) which can be imported into electroanatomical maps software.
Figure 4: 3D Multiplanar Reconstruction
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Conventional clinical 2D late gadolinium enhancement imaging can pose challenges for 
reconstruction including slice alignment. This example of 3D multiplanar reconstruction 
(performed at our own institution) yields more realistic geometry with areas of dense 
scar (red) and border zone (blue). Putative conducting channels have been indicated and 
numbered in preparation for ventricular tachycardia ablation.
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Electrophysiology and Ablation
Scar-related re-entry often relies upon functional block as well as 
anatomical barriers to conduction.108 Scar quantification methods 
do not account for these complex mechanisms, but computer 
modelling has the potential to improve risk stratification by 
combining a personalised anatomical model with simulation 
of tissue electrophysiology. This method allows simulated PVS 
performed from multiple sites in both ventricles. In a retrospective 
study of 41 patients with severe LVSD, by comparing these patient-
specific simulations with clinical outcomes, a positive ‘virtual-heart 
arrhythmia risk predictor’ simulation was associated with adverse 
outcomes (OR 4.05 (95% CI [1.20–13.8]), which is similar to published 
results from invasive PVS. Work is ongoing to determine the utility of 
such simulations in preserved LVSF.82,109
Simulated PVS methods are computationally significantly more 
challenging in NICM where myocardial fibrosis is less confluent and 
more heterogeneous, and the microscopic nature of the substrate 
is difficult to fully characterise with clinical imaging. Moreover, the 
substrate in NICM is often progressive and, as such, risk stratification at 
a single time point may fail to accurately estimate lifetime risk.
These methods are promising but are potentially limited 
by simplifications and assumptions in models of cell and tissue 
electrophysiology, the computational resources required, and the 
resolution of currently available clinical imaging. Despite encouraging 
preliminary studies, there are significant obstacles to be overcome 
before these approaches can be used routinely in clinical practice.110 
Constructing a personalised computational model of anatomy and 
electrophysiology requires calibration from clinical images and data 
that are often noisy and incomplete, so methods for embedding 
uncertainties and variability into computational models are an area of 
active research.111 Whether these approaches can be used to guide ICD 
implantation in the future remains to be seen. Technological advances 
in imaging and modelling, along with clinical studies of their utility, will 
help advance this promising concept.
Future Clinical Studies
Tissue characterisation to determine who needs and, perhaps more 
importantly, who does not need an ICD is a complex but evolving field. 
Estimates of risk currently do not allow for disease progression, and it is 
unclear how frequently investigations should be repeated, particularly for 
the dynamic substrate that occurs in some forms of NICM. The effect of 
dynamic conditions such as electrolyte disturbance, volume overload and 
myocardial ischaemia on arrhythmic risk remains unknown.
In the DANish Randomized, Controlled, Multicenter Study to Assess the 
Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-
ischemic Systolic Heart Failure on Mortality (DANISH) trial (NCT00542945), 
investigators found no overall mortality benefit for primary prevention ICD 
implantation in patients with NICM.112 However, outcomes were improved 
by ICD implantation for those in prespecified subgroups – namely younger 
patients and those with lower levels of N-terminal pro-brain natriuretic 
peptide (NT-proBNP) – who, presumably, had a lower risk of non-sudden 
death. Since CMRI studies have consistently demonstrated a higher 
arrhythmic burden in those with evidence of LGE, a clinical trial that used 
CMRI-based risk stratification in NICM patients with LVEF <35% would 
provide clinically useful information. 
Similarly, the Cardiac Magnetic Resonance GUIDEd Management of 
Mild-moderate Left Ventricular Systolic Dysfunction (CMR_GUIDE) trial 
(NCT01918215) will identify patients who have evidence of LGE but do 
not qualify for ICD treatment under current guidelines (LVEF 35–50%), 
to determine whether prophylactic ICD implantation is beneficial.113 The 
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-
Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following 
Acute Myocardial Infarction (PROTECT-ICD) trial will examine whether a 
multiparametric risk stratification algorithm (including echocardiography, 
CMRI and PVS) used post-infarction will identify those who may benefit 
from early ICD implantation.114
Contribution to Novel Therapies
Recent developments in CMRI and electrophysiology mapping 
systems have shown real-time tracking and visualisation of catheter 
position during ablation procedures to be feasible and safe for an 
‘anatomical’ ablation of the cavo-tricuspid isthmus.115,116 Advantages 
of such a system include 3D visualisation of catheter position within 
complex anatomical structures (including the ability to see surrounding 
structures) and real-time lesion evaluation. This technology has the 
potential to improve outcomes in ablation procedures, but significant 
technological challenges remain for its use in ventricular arrhythmia.
Stereotactic body radiotherapy has recently been reported as a novel, 
non-invasive treatment for VT.117,118 It is dependent on accurate anatomical 
localisation of arrhythmic substrate to determine the radiotherapy target. 
CMRI imaging is the ideal modality for treatment planning.
Conclusion
CMRI imaging can accurately quantify cardiac function, and characterise 
the myocardial substrate to refine risk stratification to identify people 
who may benefit from ICD implantation and revascularisation. Although 
large-scale trials in this area are required, it is likely that measures of 
scar quantification will become increasingly recognised by guidelines 
in future.
A multiparametric approach using imaging and other criteria may provide 
the most accurate risk assessment in the future, although the interaction 
between each of the metrics discussed is complex and requires careful 
study. Advanced techniques such as automated image segmentation and 
channel detection, or computer simulation of electrophysiology, offer 
significant potential, but are still in the early stages of development. 
Significant challenges remain in overcoming technological barriers 
and understanding how best to use the considerable information 
gained from a CMRI study. Nevertheless, CMRI offers clinicians and 
researchers an increasingly comprehensive way to diagnose, risk 
stratify and tailor the treatment of patients with cardiomyopathy.
Clinical Perspective
• Cardiac MRI (CMRI) is the gold standard imaging modality for 
ejection fraction and myocardial tissue characterisation.
• CMRI evidence of fibrosis independently predicts arrhythmic 
risk, even in multiparametric models which include clinical 
risk factors and ejection fraction, in both ischaemic and non-
ischaemic cardiomyopathies.
• CMRI can be used to inform and guide ablation procedures by 
characterising the ventricular tachycardia substrate. 
• Novel metrics such as extracellular volume mapping and channel 
identification have the potential to aid the electrophysiologist and 
provide a more robust method of risk stratification. 
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